

Sartorius Stedim Biotech to present and exhibit at the BioProcess International European Summit in Vienna

Goettingen, April 6, 2016 – Sartorius Stedim Biotech, an international leading supplier for the biopharmaceutical industry, will be presenting and exhibiting at the BioProcess International European Summit in Vienna at booth numbers 16 and 17 on April 12 and 13, 2016.

Speaker Lineup

Sartorius Stedim Biotech has gathered industry experts and thought leaders to provide informative presentations and panel discussions as follows:

- Nicolas Marceau, USP Laboratory Head at SANOFI: "ambr® 250 modular: An advanced tool to develop cell culture small-scale models representing manufacturing-scale operations"
- Daniel Galbraith, Chief Scientific Officer, Sartorius Stedim Biotech: "Impact of glycan variation on the biological activity of biosimilar monoclonal antibodies"
- Dr. Verena Emmerling, Supervisor Operations at Sartorius Stedim Biotech: "CHO expression platform: Preparing for future bioprocessing challenges"
- Miriam Monge, Director of Process Development and the Bioprocess Platform Marketing Team, Integrated Solutions, Sartorius Stedim Biotech: "Continuous processing" (panel discussion)

"The conference will serve as an excellent platform to meet industry experts and discuss the latest advances in cell culture media, feed optimization, automated microscale bioreactor systems and process analytical technologies," says Miriam Monge. Attendees will benefit from demonstrations that include the ambr® 250 modular scale-down system for microbial and mammalian cell culture, as well as showcases, videos and posters.

Pre-Conference Webinar

Sartorius Stedim Biotech's pre-conference webinar titled "Game changing innovations for mAb, recombinant proteins & biosimilar development" recently held in mid-March, highlighted the most recent developments in single-use technology and the combination of individual single-use systems to create a comprehensive, platform-based approach to bioprocess development of mAbs, biosimilars and recombinant proteins.

This webinar is now available to watch at <http://www.workcast.com> and provides a preview of solutions that the company will be showcasing at the conference.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

Press contact: Dominic Grone, Group Corporate Communications, Sartorius AG, Goettingen,
Phone:+49.(0)551.308.3324, email: dominic.grone@sartorius.com, www.sartorius.com